Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 43.56M P/E - EPS this Y 57.30% Ern Qtrly Grth -
Income -111.57M Forward P/E -0.63 EPS next Y -17.10% 50D Avg Chg -4.00%
Sales 15.45M PEG - EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -87.00%
Recommedations 2.00 Quick Ratio 3.92 Shares Outstanding 187.02M 52W Low Chg 36.00%
Insider Own 24.77% ROA -29.84% Shares Float 100.11M Beta 0.26
Inst Own 69.82% ROE -294.04% Shares Shorted/Prior 16.07M/15.81M Price 0.68
Gross Margin 100.00% Profit Margin - Avg. Volume 248,227 Target Price 6.35
Oper. Margin -438.32% Earnings Date May 9 Volume 85,872 Change 0.19%
About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies, Inc. News
07:00 AM Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
04/29/24 These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
04/20/24 Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
04/15/24 Certain Biotech Investors Get an Early Look at Results. Is That Fair?
04/05/24 Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/24/24 News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts
03/21/24 Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations
03/20/24 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
03/20/24 Q4 2023 Taysha Gene Therapies Inc Earnings Call
03/19/24 Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
03/14/24 Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
02/29/24 Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
02/15/24 Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
02/13/24 Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA),
01/31/24 7 Micro-Cap Stocks That Could Majorly Surprise Investors
01/22/24 Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
01/15/24 3 Growth Stocks That Could Go Parabolic in 2024
01/10/24 Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
12/19/23 Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
11/29/23 Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
TSHA Chatroom

User Image Jarvis7424 Posted - 29 minutes ago

$TSHA great news

User Image Stock_Titan Posted - 2 hours ago

$TSHA Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome https://www.stocktitan.net/news/TSHA/taysha-gene-therapies-announces-regenerative-medicine-advanced-dhg5zcw63am5.html

User Image bmjmj1 Posted - 19 hours ago

$TSHA bought 1,000 more

User Image DIDO555 Posted - 04/30/24

@G101SPM $TSHA

User Image bmjmj1 Posted - 04/29/24

$TSHA added more

User Image Jarvis7424 Posted - 04/29/24

$TSHA strong buy? 👀

User Image TipRanks Posted - 04/29/24

These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler https://www.tipranks.com/news/article/these-2-strong-buy-penny-stocks-could-rally-to-9-says-piper-sandler $UNCY $TSHA

User Image bmjmj1 Posted - 04/28/24

$MTTR to my fellow longs, check out $TSHA A gamble but if it happens, huge upside!

User Image bmjmj1 Posted - 04/28/24

$TSHA with this continuing data that looks promising for a cure, this gonna be at $20s in a year. Let’s go!!!!

User Image derider58 Posted - 04/24/24

$TSHA It's time!

User Image _www_larval_com_ Posted - 04/19/24

$TSHA just reverted 4% higher to -3% (~1Mv) a few minutes ago, 04/19 options, follow for more volatility.

User Image Stockbricks Posted - 04/19/24

$TSHA why is this going g down with huge interest and great results.

User Image BB_king Posted - 04/18/24

$TSHA it’s time

User Image Barsofgreen Posted - 04/16/24

$TSHA did you reload?

User Image strongtrendtrader Posted - 04/15/24

$TSHA weekly trend

User Image BB_king Posted - 04/12/24

$TSHA not missing the chance to reload this time

User Image Doozio Posted - 04/11/24

ANGI is a ho. TNYA needs papa huckleberry. $Tsha chop chop huckleberries. Scrabble with a 🦄👑 n let’s bang bro!

User Image jpcdmd Posted - 04/11/24

$TSHA I think it has one more trip to the high $2's before breaking $3.50

User Image Barsofgreen Posted - 04/11/24

$TSHA need to break 3.50

User Image radhadman Posted - 04/11/24

$TSHA break that resistance!

User Image NYEric Posted - 04/11/24

$TSHA

User Image NYEric Posted - 04/11/24

$TSHA Slow steady climb higher

User Image strongtrendtrader Posted - 04/10/24

$TSHA breakout on weekly this week or next week?

User Image _StockTrader Posted - 04/10/24

Real-Time Stock Data $TSHA Price: 3.22 Volume: 3686881 Market Cap: 597522496 PE Ratio: -6.65625 Powered by: AITX

User Image working_girl Posted - 04/10/24

$TSHA Definitely outperforming $SPY today lol

User Image Msnlrainey Posted - 04/10/24

$TSHA its a red day what do you expect?

User Image radhadman Posted - 04/10/24

$TSHA just not enough power here. should be able to blast past 3.4

User Image Wigglyick Posted - 04/10/24

@DonCorleone77 @Im_not_Mr_Lebowski @Cash4freedom @MaverikIT @net0trader @IsabellaDC @RonIsWrong $TSHA Doing well in this mess.

User Image The_Bear_Slayer Posted - 04/10/24

$TSHA

User Image Kovyarmy Posted - 04/10/24

$TSHA 💥

Analyst Ratings
Cantor Fitzgerald Overweight Apr 30, 24
Cantor Fitzgerald Overweight Apr 19, 24
Cantor Fitzgerald Overweight Apr 18, 24
Needham Buy Apr 11, 24
Piper Sandler Overweight Apr 9, 24
Canaccord Genuity Buy Mar 21, 24
Chardan Capital Buy Mar 21, 24
JMP Securities Market Outperform Mar 20, 24
Cantor Fitzgerald Overweight Mar 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Manning Paul B 10% Owner 10% Owner Nov 17 Buy 1.63 100,000 163,000 16,566,667 11/20/23
Alam Kamran Chief Financial Offi.. Chief Financial Officer Aug 24 Sell 2.33 33,000 76,890 258,042 08/25/23
Manning Paul B 10% Owner 10% Owner Aug 16 Buy 0.90 16,466,667 14,820,000 16,466,667 08/16/23
Stalfort John A III Director Director Aug 16 Buy 0.9 777,778 700,000 999,381 08/16/23
Nolan Sean P. Chief Executive Offi.. Chief Executive Officer Aug 16 Buy 0.90 444,444 400,000 1,535,545 08/16/23
Donenberg Phillip B. Director Director Aug 16 Buy 0.90 111,111 100,000 114,111 08/16/23
Session R.A. II 10% Owner 10% Owner Jun 22 Sell 0.7 28,608 20,026 8,957,619 06/26/23
Alam Kamran Chief Financial Offi.. Chief Financial Officer Aug 23 Sell 3.47 3,325 11,538 266,121 08/24/22
Alam Kamran Chief Financial Offi.. Chief Financial Officer Aug 18 Sell 3.71 28,675 106,384 269,446 08/22/22
PRASAD SUYASH CMO and Head of R&D CMO and Head of R&D Jul 05 Sell 3.65 12,861 46,943 530,589 07/07/22
PRASAD SUYASH CMO and Head of R&D CMO and Head of R&D Jun 29 Sell 3.69 50,139 185,013 543,450 07/01/22
Manning Paul B Director Director Feb 02 Buy 7.8 201,602 1,572,496 2,091,704 02/04/22
Nagendran Sukumar Director Director Feb 02 Buy 8.01 10,000 80,100 29,226 02/03/22
Donenberg Phillip B. Director Director Feb 02 Buy 7.78 3,000 23,340 3,000 02/03/22